ABBOTT LABORATORIES Form 8-K March 14, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

March 8, 2017

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in its charter)

Illinois
(State or other Jurisdiction of Incorporation)

1-2189 (Commission File Number) 36-0698440 (IRS Employer Identification No.)

100 Abbott Park Road

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant s telephone number, including area code: (224) 667-6100

	appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of ving provisions:
0	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o 240.14d	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR i-2(b))
o 240.13e-	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR -4(c))

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 8, 2017, Michael J. Warmuth, Executive Vice President, Established Pharmaceuticals, informed Abbott that he will be retiring as an officer of the company on March 31, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES

Date: March 14, 2017 By: /s/ Brian B. Yoor

Brian B. Yoor

Executive Vice President, Finance and

Chief Financial Officer